BACKGROUND: Subgroups of breast cancer that have an impaired response to endocrine treatment, despite hormone receptor positivity, are still poorly defined. Breast cancer can be subdivided according to standard pathological parameters including histological type, grade, and assessment of proliferation. These parameters are the net result of combinations of genetic alterations effecting tumour behaviour and could potentially reflect subtypes that respond differently to endocrine treatment. AIMS: To investigate the usefulness of these parameters as predictors of the response to tamoxifen in premenopausal women with breast cancer. MATERIALS/ METHODS: Clinically established pathological parameters were assessed and related to the tamoxifen response in 500 available tumour specimens from 564 premenopausal patients with breast cancer randomised to either two years of tamoxifen or no treatment with 14 years of follow up. Proliferation was further evaluated by immunohistochemical Ki-67 expression. RESULTS:Oestrogen receptor positive ductal carcinomas responded as expected to tamoxifen, whereas the difference in recurrence free survival between control and tamoxifen treated patients was less apparent in the relatively few lobular carcinomas. For histological grade, there was no obvious difference in treatment response between the groups. The relation between proliferation and tamoxifen response seemed to be more complex, with a clear response in tumours with high and low proliferation, whereas tumours with intermediate proliferation defined by Ki-67 responded more poorly. CONCLUSIONS: Clinically established pathology parameters seem to mirror the endocrine treatment response and could potentially be valuable in future treatment decisions for patients with breast cancer.
RCT Entities:
BACKGROUND: Subgroups of breast cancer that have an impaired response to endocrine treatment, despite hormone receptor positivity, are still poorly defined. Breast cancer can be subdivided according to standard pathological parameters including histological type, grade, and assessment of proliferation. These parameters are the net result of combinations of genetic alterations effecting tumour behaviour and could potentially reflect subtypes that respond differently to endocrine treatment. AIMS: To investigate the usefulness of these parameters as predictors of the response to tamoxifen in premenopausal women with breast cancer. MATERIALS/ METHODS: Clinically established pathological parameters were assessed and related to the tamoxifen response in 500 available tumour specimens from 564 premenopausal patients with breast cancer randomised to either two years of tamoxifen or no treatment with 14 years of follow up. Proliferation was further evaluated by immunohistochemical Ki-67 expression. RESULTS: Oestrogen receptor positive ductal carcinomas responded as expected to tamoxifen, whereas the difference in recurrence free survival between control and tamoxifen treated patients was less apparent in the relatively few lobular carcinomas. For histological grade, there was no obvious difference in treatment response between the groups. The relation between proliferation and tamoxifen response seemed to be more complex, with a clear response in tumours with high and low proliferation, whereas tumours with intermediate proliferation defined by Ki-67 responded more poorly. CONCLUSIONS: Clinically established pathology parameters seem to mirror the endocrine treatment response and could potentially be valuable in future treatment decisions for patients with breast cancer.
Authors: M Fernö; B Baldetorp; P O Bendahl; A Borg; S B Ewers; H Olsson; S Rydén; H Sigurdsson; D Killander Journal: Breast Cancer Res Treat Date: 1995 Impact factor: 4.872
Authors: R Silvestrini; M G Daidone; M Mastore; G Di Fronzo; D Coradini; P Boracchi; P Squicciarini; B Salvadori; U Veronesi Journal: J Clin Oncol Date: 1993-06 Impact factor: 44.544
Authors: R I Nicholson; N Bouzubar; K J Walker; R McClelland; A R Dixon; J F Robertson; I O Ellis; R W Blamey Journal: Eur J Cancer Date: 1991 Impact factor: 9.162
Authors: O Stål; L Skoog; L E Rutqvist; J M Carstensen; S Wingren; S Sullivan; A C Andersson; M Dufmats; B Nordenskjöld Journal: Br J Cancer Date: 1994-12 Impact factor: 7.640
Authors: Katja Lundgren; Nicholas P Tobin; Sophie Lehn; Olle Stål; Lisa Rydén; Karin Jirström; Göran Landberg Journal: J Mol Diagn Date: 2011-05 Impact factor: 5.568
Authors: Sophie Lehn; Nicholas P Tobin; Pontus Berglund; Kristina Nilsson; Andrew H Sims; Karin Jirström; Pirkko Härkönen; Rebecca Lamb; Göran Landberg Journal: Am J Pathol Date: 2010-10-22 Impact factor: 4.307
Authors: Akshay Anand; Kul R Singh; Surender Kumar; Nuzhat Husain; Jitendra K Kushwaha; Abhinav A Sonkar Journal: Breast Care (Basel) Date: 2017-06-16 Impact factor: 2.860
Authors: Lajos Pusztai; Jong-Hyeon Jeong; Yun Gong; Jeffrey S Ross; Chungyeul Kim; Soonmyung Paik; Roman Rouzier; Fabrice Andre; Gabriel N Hortobagyi; Norman Wolmark; W Fraser Symmans Journal: J Clin Oncol Date: 2009-08-10 Impact factor: 44.544
Authors: Otto Metzger Filho; Anita Giobbie-Hurder; Elizabeth Mallon; Barry Gusterson; Giuseppe Viale; Eric P Winer; Beat Thürlimann; Richard D Gelber; Marco Colleoni; Bent Ejlertsen; Marc Debled; Karen N Price; Meredith M Regan; Alan S Coates; Aron Goldhirsch Journal: J Clin Oncol Date: 2015-07-27 Impact factor: 44.544